Preclinical Studies of OBI-999: A Novel Globo H–Targeting Antibody–Drug ConjugateMing-Chen Yang(Efficient Pharma Management (Taiwan)), Ming‐Tain Lai(Leo Pharma (Australia))Molecular Cancer TherapeuticsMarch 15, 202110.1158/1535-7163.mct-20-0763Cited by 30SaveCiteExport RISWatch citationsRelated PapersDoravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial|The Lancet HIV|2018|145Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions|Viruses|2016|18